Pumch
Hospitals & Physicians Clinics · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1 Shuaifuyuan, Beijing, Beijing, 100730,...Website
www.pumch.cnRevenue
$631.2 MillionIndustry
About Pumch
Pumch Org Chart
Is Pumch your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pumch launches new products
Congratulate Masked Content for being promoted to Masked Content at Pumch
Funding: Get notified immidiatlly once Pumch has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Pumch recently announced quarterly report
Pumch, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Pumch had a recent Job posting/layoffs
Check if Pumch has recently received funding, and reach out quickly before it becomes old news!
Check out if Pumch is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Pumch is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
Pumch is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about Pumch.
Pumch Tech Stack
A closer look at the technologies used by Pumch
Most Recent Scoops
Pumch News & Media
Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results
SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's...CANbridge Signs Collaboration Agreement with the Peking Union Medical College on Rare Disease Research
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals enters into collaborative rare disease research agreement with the University of Peking Union Medical CollegeFulgent Genetics Announces Launch of Next Generation Sequencing (NGS) Test to Detect Coronavirus Disease (COVID-19)
Fulgent Genetics will partner with MedScan Laboratory to launch one of the market’s first COVID-19 tests based on comprehensive Next Generation Sequencing technology Fulgent Genetics will partner with MedScan Laboratory to launch one of the market’s first COVID-19 tests based on comprehensive Next Generation Sequencing technologyEarly Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors
WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announced today that Professor Zhaohui Zhu et. al. of the Department of Nuclear Medicine, Peking Union Medical College Hospital (PUMC), Beijing, China will present a talk entitled “Safety and Response of an Evans Blue-modified 177Lu-labeled Octreotate (EBTATE) in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study” at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Anaheim thi
Top Hospitals & Physicians Clinics Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Pumch
Peking Union Medical College Hospital (PUMCH), an institutional Faculty of Clinical Medicine affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), is a renowned general hospital in China with a prestigious historical background. Designated by Ministry of Health, PUMCH is the national medical technica... Read More